Cybin Closes $175 Million Financing to Advance Phase 3 Psychedelic Depression Treatment
核心洞察
Cybin successfully closed a $175 million registered direct offering to fund its breakthrough psychedelic drug development programs targeting mental health conditions (搜索).
The financing will advance CYB003, a deuterated psilocin analog with FDA Breakthrough Therapy Designation, currently in Phase 3 trials for major depressive disorder (搜索).
Proceeds will also support development of CYB004 for generalized anxiety disorder (搜索) and CYB005, while repaying existing debt obligations.
Cybin Inc. (搜索), a Phase 3 clinical-stage neuropsychiatry company developing psychedelic-based treatments for mental health conditions (搜索), has successfully closed a $175 million registered direct offering to advance its breakthrough drug development programs. The financing represents a significant milestone for the company as it progresses multiple novel compounds through clinical trials.
The offering consisted of 22,277,750 common shares and 4,605,500 pre-funded warrants priced at $6.51 per share, generating aggregate gross proceeds of $175,009,911.45. Each security includes 0.35 of a warrant exercisable at $8.14 per share, with expiration tied to key clinical milestones including topline data from the APPROACH trial of CYB003 in major depressive disorder (搜索).
Strong Institutional Support
The financing attracted participation from prominent healthcare investors including Venrock Healthcare Capital Partners (搜索), OrbiMed (搜索), Point72 (搜索), Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners, and Ally Bridge Group.
Jefferies, TD Cowen, and Cantor served as joint lead placement agents, with Bloom Burton Securities Inc. acting as a placement agent for the offering.
Advancing Breakthrough Psychedelic Therapies
Cybin is currently developing CYB003, a proprietary deuterated psilocin analog that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (搜索). The compound is being evaluated in Phase 3 studies for the adjunctive treatment of major depressive disorder (搜索), addressing a significant unmet medical need in mental healthcare.
The company's pipeline also includes CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 studies for generalized anxiety disorder (搜索). Additionally, Cybin maintains a research pipeline of investigational 5-HT-receptor (搜索) focused compounds.
Strategic Use of Proceeds
The company intends to allocate the net proceeds from the offering across several strategic priorities. A portion will be used to repay outstanding unsecured convertible debentures held by High Trail Special Situations LLC, strengthening the company's balance sheet. The majority of funds will advance the CYB003, CYB004, and CYB005 programs through their respective clinical development phases.
Additional proceeds will support working capital and general corporate purposes as Cybin continues to build its operational capabilities across Canada, the United States, the United Kingdom, and Ireland.
Clinical Development Timeline
The warrant structure provides insight into anticipated clinical milestones, with exercise conditions tied to the publication of topline data from the APPROACH trial of CYB003. The warrants expire on the earlier of June 30, 2027, thirty days following publication of the APPROACH trial results, or thirty days after the company exercises acceleration rights if shares trade above $19.53 for five consecutive days.
Founded in 2019, Cybin has positioned itself as a leader in the emerging psychedelic medicine space, developing novel treatment options for patients suffering from mental health conditions (搜索). The company emphasizes that rigorous scientific research and clinical trials are needed to establish the efficacy of psychedelic compounds, and no medical or treatment claims are made about its investigational products.